These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 20132625)
1. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. de Castro L; do Brasil PE; Monteiro TP; Rolla VC Int J Tuberc Lung Dis; 2010 Mar; 14(3):332-40. PubMed ID: 20132625 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Chien JY; Huang RM; Wang JY; Ruan SY; Chien YJ; Yu CJ; Yang PC Int J Tuberc Lung Dis; 2010 May; 14(5):616-21. PubMed ID: 20392356 [TBL] [Abstract][Full Text] [Related]
3. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Mo P; Zhu Q; Teter C; Yang R; Deng L; Yan Y; Chen J; Zeng J; Gui XE Int J Infect Dis; 2014 Nov; 28():95-100. PubMed ID: 25218771 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. Padmapriyadarsini C; Chandrabose J; Victor L; Hanna LE; Arunkumar N; Swaminathan S J Postgrad Med; 2006; 52(2):92-6. PubMed ID: 16679670 [TBL] [Abstract][Full Text] [Related]
5. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. Kim WS; Lee SS; Lee CM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ; Hong JW; You HS; Cho HC BMC Infect Dis; 2016 Feb; 16():50. PubMed ID: 26833347 [TBL] [Abstract][Full Text] [Related]
8. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment. Trigo C; do Brasil PE; Costa MJ; de Castro L J Viral Hepat; 2016 Dec; 23(12):1027-1035. PubMed ID: 27624908 [TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986 [TBL] [Abstract][Full Text] [Related]
10. Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study. Maruza M; Albuquerque MF; Braga MC; Barbosa MT; Byington R; Coimbra I; Moura LV; Batista JD; Diniz GT; Miranda-Filho DB; Lacerda HR; Rodrigues LC; Ximenes RA Int J Tuberc Lung Dis; 2012 May; 16(5):618-24. PubMed ID: 22410415 [TBL] [Abstract][Full Text] [Related]
11. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Zheng J; Guo MH; Peng HW; Cai XL; Wu YL; Peng XE Epidemiol Infect; 2020 Nov; 148():e290. PubMed ID: 33222713 [TBL] [Abstract][Full Text] [Related]
12. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595 [TBL] [Abstract][Full Text] [Related]
14. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920 [TBL] [Abstract][Full Text] [Related]
15. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037 [TBL] [Abstract][Full Text] [Related]
16. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: A systematic review and meta-analysis. Chou C; Veracruz N; Chitnis AS; Wong RJ J Viral Hepat; 2022 Dec; 29(12):1107-1114. PubMed ID: 36138556 [TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G; BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804 [TBL] [Abstract][Full Text] [Related]
18. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Tostmann A; van den Boogaard J; Semvua H; Kisonga R; Kibiki GS; Aarnoutse RE; Boeree MJ Trop Med Int Health; 2010 Feb; 15(2):268-72. PubMed ID: 20409289 [TBL] [Abstract][Full Text] [Related]
19. Acute liver enzyme elevations in HIV-1-infected patients. Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283 [TBL] [Abstract][Full Text] [Related]
20. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Warmelink I; ten Hacken NH; van der Werf TS; van Altena R Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]